Medoflucon

Fluconazole, the active ingredient in Medoflucon, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including candidiasis of the vagina, mouth, esophagus, bloodstream and certain central nervous system infections, and is used to prevent fungal disease in immunocompromised patients.

GNH USA supplies Medoflucon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Medoflucon is an azole antifungal indicated for several Candida‑related infections and for fungal prophylaxis in vulnerable patients. - Vulvovaginal candidiasis: reduces yeast overgrowth and relieves itching, discharge and irritation. - Oropharyngeal and esophageal candidiasis: clears infection and improves swallowing and oral comfort. - Systemic candidiasis: eradicates bloodstream Candida species and prevents dissemination. - Cryptococcal meningitis (adjunct therapy): enhances antifungal activity in the central nervous system. - Prevention of fungal infections in immunocompromised patients: provides prophylaxis during chemotherapy or transplantation.

Fluconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Rash: mild skin irritation or erythema. - Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects: - Hepatotoxicity: potential liver injury requiring monitoring. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: rare but life‑threatening allergic response. - QT prolongation: cardiac rhythm disturbance in susceptible individuals.

Before prescribing Medoflucon, clinicians should consider several safety factors. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic disease: monitor liver enzymes regularly during therapy. - Concomitant medications: review for potential drug‑drug interactions. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluconazole interacts with several medicines; careful assessment is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase fluconazole plasma levels. - QT‑prolonging agents (e.g., cisapride, quinidine): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Warfarin: fluconazole can enhance anticoagulant effect, requiring INR monitoring. - Oral hypoglycemics (e.g., sulfonylureas): may increase blood‑sugar‑lowering effect. - Rifampin: can reduce fluconazole concentrations, potentially compromising efficacy.